[
    {
        "Header Number": "1",
        "Title": "Amendments from Previous Version(s)",
        "Content": "",
        "Sub-sections": []
    },
    {
        "Header Number": "2",
        "Title": "Introduction",
        "Content": "",
        "Sub-sections": [
            {
                "Header Number": "2.1",
                "Title": "Study Design",
                "Content": "NIS Protocol B1771009 \nStatistical Analysis Plan \n \n \n \nPFIZER CONFIDENTIAL \nPage 7 of 42 \n \nFlow chart on documentation sequences for patients suffering from mRCC \n \n \n1st Pfizer therapy sequence \nDocumentation \nof treatment \nwith non-\nPfizer \ntherapies \n2nd Pfizer therapy sequence \nSurvival \ninformation \nBaseline \nvisit \nFollow-\nup visit \nevery 8 \u2013 \n12 weeks \nFinal / \ndiscontinuation \nof treatment \nevery 8 \u2013 12 \nmonth \nBaseline \nat time of \nstart of 2nd \nPfizer \ntherapy \nFollow-\nup visit \nevery 8 \u2013 \n12 weeks \nFinal / \ndiscontinuation \nof treatment \n12 month after \ndiscontinuation \nand then every \n6 months \nDemography \nx \nx \nx \n \nx \nx \nx \nx \nIn- and \nexclusion \ncriteria \nx \n \n \n \n \n \n \n \nPatient consent \nx \n \n \n(x) \n \n \n \n \nTumor \nanamnesis \nx \n \n \n \nx \n \n \n \nKarnofsky \nPerformance \nstatus /  \nheight / weight \nx \nx \n \n \nx \nx \n \n \nCCI\nNIS Protocol B1771009 \nStatistical Analysis Plan \n \n \n \nPFIZER CONFIDENTIAL \nPage 8 of 42 \n \nTherapy / \nMedication \n \n \n \n \n \n \n \n \nPrior \nmedication \nx \n \n \n \n \n \n \n \nConcomitant \nmedication \nx \n \n \n \nx \n \n \n \nTumor \ntreatment \nx \nx \n \nx \nx \nx \n \nx \nSafety \n \n \n \n \n \n \n \n \nConcomitant \ndiseases / \nphysical \nexamination \nx \n \n \n \nx \n \n \n \nLaboratory \nvalues \nx \nx \n \n \nx \nx \n \n \nBlood pressure \nx \nx \n \n \nx \nx \n \n \nECG \nx \nx \n \n \nx \nx \n \n \nEchocardiogram \nx \nx \n \n \nx \nx \n \n \nAssessment of \npain \nx \nx \n \n \nx \nx \n \n \nAdverse events \nx \nx \nx \nx \nx \nx \nx \n \nCCI\nNIS Protocol B1771009 \nStatistical Analysis Plan \n \n \n \nPFIZER CONFIDENTIAL \nPage 9 of 42 \n \nEfficacy \n \n \n \n \n \n \n \n \nRisk prognosis \nx \n \n \n \nx \n \n \n \nCT / MRT \nx \nx \n \n \n \nx \n \n \nUltrasound \nx \nx \n \n \n \nx \n \n \nChest X-ray \nx \nx \n \n \n \nx \n \n \nTumor \nassessment \n \nx \n \nx \n \nx \n \n \nPhysician\u2019s \nassessment of \nefficacy and \ntolerability \n \nx \n \n \n \nx \n \n \nPhysician\u2019s \noverall \nassessment of \ntreatment \nresponse \n \n \nx \nx \n \n \nx \n \nPRO: quality of \nlife \nx \nx \n \n \nx \nx \n \n \n \nCCI\n",
                "Sub-sections": []
            },
            {
                "Header Number": "2.2",
                "Title": "Study Objectives",
                "Content": "",
                "Sub-sections": []
            }
        ]
    },
    {
        "Header Number": "3",
        "Title": "Interim Analyses",
        "Content": "",
        "Sub-sections": []
    },
    {
        "Header Number": "4",
        "Title": "Hypotheses and decision rules",
        "Content": "",
        "Sub-sections": [
            {
                "Header Number": "4.1",
                "Title": "Statistical Hypotheses",
                "Content": "",
                "Sub-sections": []
            },
            {
                "Header Number": "4.2",
                "Title": "Statistical decision rules",
                "Content": "",
                "Sub-sections": []
            }
        ]
    },
    {
        "Header Number": "5",
        "Title": "Analysis Sets/populations",
        "Content": "",
        "Sub-sections": [
            {
                "Header Number": "5.1",
                "Title": "Effectiveness analysis set",
                "Content": "",
                "Sub-sections": []
            },
            {
                "Header Number": "5.2",
                "Title": "Safety analysis set",
                "Content": "",
                "Sub-sections": []
            },
            {
                "Header Number": "5.3",
                "Title": "Other analysis set",
                "Content": "",
                "Sub-sections": []
            },
            {
                "Header Number": "5.4",
                "Title": "Subgroups",
                "Content": "",
                "Sub-sections": []
            }
        ]
    },
    {
        "Header Number": "6",
        "Title": "Endpoints and covariates",
        "Content": "",
        "Sub-sections": [
            {
                "Header Number": "6.1",
                "Title": "Efficacy/Effectiveness Endpoint(s)",
                "Content": "",
                "Sub-sections": []
            },
            {
                "Header Number": "6.2",
                "Title": "Safety Endpoints",
                "Content": "",
                "Sub-sections": []
            },
            {
                "Header Number": "6.4",
                "Title": "Covariates",
                "Content": "NIS Protocol B1771009                                                        Statistical Analysis Plan _____________________________________________________________________  PFIZER CONFIDENTIAL  Page 15 of 42  Patients with GIST will be grouped according to the physicians risk assessment at time of inclusion in the study and by their prognosted risk according to Fletcher risk table at time of primary diagnosis.  ",
                "Sub-sections": [
                    {
                        "Header Number": "6.4.1",
                        "Title": "Motzer score",
                        "Content": "  According to the  five risk factors are defined: low Karnofsky performance status (< 80%), high LDH (> \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 300 U/L), low \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 13 g/dL for male patients, < 11.5 g/dL for female patients), high corrected serum calcium (> 10 mg/dL) and time from diagnosis to start of Torisel\u00ae or Sutent\u00ae treatment less than one one year. A patient without any risk factor present at baseline visit belongs to the favorable-risk group, one with one or two risk factors present at baseline belongs to the intermediate-risk group and one with three or more risk factors present at baseline belongs to the poor-risk group. The corrected serum calcium value will be computed from the values of serum calcium and serum albumin according to the following formula: Corrected Serum Calcium (mg/dL)   = Calcium (mmol/L) * 4.008 \u2013 0.707 * (Albumin (g/L) / 10 \u2013 3.4). Modified  The modification of the  adds one further risk factor: at least 2 sites of organ metastases. The assignment to the risk groups and the calculation of corrected serum calcium remains unchanged. Within this study modified  was only determined for 1st line patients. Only two categori\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd= non poor\u201d.  for previously treated patients The ",
                        "Sub-sections": [
                            {
                                "Header Number": "N/A",
                                "Title": "Motzer score",
                                "Content": "",
                                "Sub-sections": []
                            },
                            {
                                "Header Number": "N/A",
                                "Title": "Modified Motzer score",
                                "Content": " The modification of the Motzer score adds one further risk factor: at least 2 sites of organ metastases. The assignment to the risk groups and the calculation of corrected serum calcium remains unchanged. Within this study modified Motzer score was only determined for 1st line patients. Only two categori\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd= non poor\u201d.  The ",
                                "Sub-sections": []
                            },
                            {
                                "Header Number": "N/A",
                                "Title": "Motzer score for previously treated patients",
                                "Content": " The  is based on the three risk factors: low Karnofsky performance status (< 80%), low hemoglobin (< lower limit of \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd< 13 g/dL for male patients, < 11.5 g/dL for female patients) and high corrected serum calcium (> 10 mg/dL). The score is only defined for patients with at least one previous systemic treatment of RCC. A patient is assigned to the favourable-risk groups, if no risk CCICCINIS Protocol B1771009                                                        Statistical Analysis Plan _____________________________________________________________________  PFIZER CONFIDENTIAL  Page 16 of 42  factor is present, to the intermediate-risk group, if one risk factor is present and to the poor-risk, if two or three risk factors are present.  ",
                                "Sub-sections": []
                            }
                        ]
                    },
                    {
                        "Header Number": "6.4.2",
                        "Title": "Mantle Cell Lymphoma International Prognostic Index (MIPI)",
                        "Content": "  MIPI score is defined as  Score = 0.0353 * age (yrs) + 0.6978 * [ECOG > 1 {yes/no}]  + 1.367*log10(LDH/ULN LDH)  + 0.9393*log10(Leukocyte count [/\u03bcl]) Low risk if Score < 5.7 Intermediate risk \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd High risk \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd If all data necessary to compute MIPI score are available, the calculated risk will be used for analyses of current MIPI. Otherwise and for the time of primary diagnosis the value documented by the physician will be used. ",
                        "Sub-sections": []
                    },
                    {
                        "Header Number": "6.4.3",
                        "Title": "Fletcher Risk Table (NIH Risk Table)",
                        "Content": "",
                        "Sub-sections": []
                    }
                ]
            }
        ]
    },
    {
        "Header Number": "7",
        "Title": "Handling of Missing Values",
        "Content": "NIS Protocol B1771009                                                        Statistical Analysis Plan \n_____________________________________________________________________ \n \nPFIZER CONFIDENTIAL \n \nPage 17 of 42 \n \n\ufffd If at least three (two for Motzer score for pretreated patients) risk factors are present, \nmissing values for the remaining can be ignored and the patient will be assigned to \nthe poor risk group. \n\ufffd If the calcium value is given, but the albumin value is missing, than calcium will be \ninterpreted as a risk factor if the calcium value is above 11 mg/dL. \n\ufffd If the hemoglobin value is missing, but a clinically significant low hemoglobin value \nor anemia is documented as comorbidity, than this will be interpreted as a risk factor \npresent. \n\ufffd If the LDH value is missing, but a clinically significant high LDH value is \ndocumented as comorbidity, than this will be interpreted as a risk factor present. \n \nWith the protocol amendment including mRCC patients being treated with axitinib some \nadditional information was asked for in the CRF. This implies missing values for patients \ndocumented under earlier versions of protocol and CRF. The percentage of missings due \nto this reason will not be reported in tables extra. With amendment VI interim treatment \nwith non-Pfizer products was included. This data will only be analyzed for patients \ndocumented under amendment VI. \nCCI\nCCI\n",
        "Sub-sections": []
    },
    {
        "Header Number": "8",
        "Title": "Statistical Methodology and Statistical Analyses",
        "Content": "",
        "Sub-sections": [
            {
                "Header Number": "8.1",
                "Title": "Statistical methods",
                "Content": "",
                "Sub-sections": [
                    {
                        "Header Number": "8.1.1",
                        "Title": "Analysis Of Categorical And Continuous Data",
                        "Content": "    Categorical data will be analyzed by presenting frequency tables (absolute and relative frequencies/ adjusted and not adjusted). For continuous data the sample statistics mean, standard deviation, median, minimum and maximum, and quartiles are calculated. For incidence rates 95% confidence intervals will be presented. Data measured several times during the study are analyzed by visit presenting absolute and relative differences to baseline for numerical data and shift tables for categorical data. Agreement between the risks assigned to patients by the risk scores and physician\u2019s prognosis of patients risk will be measured using Cohens kappa-statistic.  ",
                        "Sub-sections": []
                    },
                    {
                        "Header Number": "8.1.2",
                        "Title": "Analysis Of Survival Data",
                        "Content": "",
                        "Sub-sections": []
                    }
                ]
            },
            {
                "Header Number": "8.2",
                "Title": "Statistical Analyses",
                "Content": "",
                "Sub-sections": [
                    {
                        "Header Number": "8.2.1",
                        "Title": "Summary of Efficacy/ Effectiveness Analyses",
                        "Content": "   Not applicable  ",
                        "Sub-sections": []
                    },
                    {
                        "Header Number": "8.2.2",
                        "Title": "Safety Analyses",
                        "Content": " Adverse events will be analyzed giving absolute and relative frequencies in total and by MedDRA system organ classes and preferred term. Serious adverse events will be analyzed separately in the same manner.  CCICCICCINIS Protocol B1771009                                                        Statistical Analysis Plan \n_____________________________________________________________________ \n \nPFIZER CONFIDENTIAL \n \nPage 19 of 42 \n \nAdverse events will presented within each treatment (temsirolimus, sunitinib, axitinib) \nand for all non-Pfizer treatments in total and by treatment. \nAdditionally the absolute and relative frequency of patients with premature \ndiscontinuation will be presented in total and by reason for premature discontinuation. \nPrior and concomitant medication will be presented showing frequency tables. \nLaboratory results and ECG results will be presented by visit. \nPhysician\u2019s assessment of tolerability will be analyzed presenting sample statistics. \nCCI\nCCI\nNIS Protocol B1771009                                                        Statistical Analysis Plan _____________________________________________________________________  PFIZER CONFIDENTIAL Page 20 of 42  ",
                        "Sub-sections": []
                    },
                    {
                        "Header Number": "8.2.3",
                        "Title": "Summary of Analyses",
                        "Content": "   Outcome Analysis Set Supports Protocol Objective Number Subgroups Statistical Method  Covariates/ Strata Missing Data Demographic characteristics: age, height, weight, BMI, sex Safety, EAS 4 None Sample statistics None Excluded Incidence of treatment-emergent adverse events Safety 3 - Patients receiving CYP3A4 inducing concomitant medication (only patients treated with temsirolimus) - Patients receiving CYP3A4 inhibiting concomitant medication (only patients treated with temsirolimus) Rate by SOC and PT Non-serious AE, serious AE Excluded Discontinuations due to AE Safety 3 None Rate by SOC and PT None Excluded Discontinuation from Study Safety 3 None Rate for reason for discontinuation None Excluded Serious Adverse Events Safety 3 None Rate by SOC and PT None Excluded Deaths Safety 3 None - Rates for reason for death - Listing of deaths None Excluded Laboratory values Safey 3 None Sample statistics by parameter and visit None Excluded CCINIS Protocol B1771009                                                        Statistical Analysis Plan \n_____________________________________________________________________ \n \nPFIZER CONFIDENTIAL \nPage 21 of 42 \n \nOutcome \nAnalysis Set \nSupports \nProtocol \nObjective \nNumber \nSubgroups \nStatistical Method  \nCovariates/ Strata \nMissing Data \nGlobal tolerability \nassessment \nSafety \n2 \nNone \nFrequency table \nNone \nExcluded \nOverall survival \nEAS \n1 \n- 1st line patients \nKaplan-Meier \nestimates; Kaplan-\nMeier curves;  \nLog-rank test \n- indication mRCC, GIST, MCL \n- risk prognosis \n- line of treatment \n- low vs. high LDH \n- response to prior therapy \n- \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd \n \nProgression free \nsurvival \nEAS \n1 \n- 1st line patients \nKaplan-Meier \nestimates; Kaplan-\nMeier curves \n- indication mRCC, GIST, MCL \n- risk prognosis \n- line of treatment \n- low vs. high LDH \n- response to prior therapy \n- \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd \n- histology (clear cell vs. non-clear cell) \n \nResponse to therapy \nEAS \n1 \n- risk prognosis \nFrequency table \nNone \nExcluded \nPhysician\u2019s global \nassessment \nEAS \n1 \nNone \nSample statistics by \nvisit \nRisk prognosis \nExcluded \nKarnofsky \nPerformance Index \nEAS \n4, 5 \nNone \nSample statistics by  \nvisit \nOnly GIST, mRCC \nExcluded \nECOG Performance \nScore \nEAS \n4, 5 \n- risk prognosis \nFrequency table; shift \ntables \nOnly MCL \nExcluded \nFKSI-15 \nEAS \n6 \n- risk prognosis \nSample statistics \nOnly mRCC \nExcluded \nEQ-5D \nEAS \n6 \n- risk prognosis \nFrequency table for \nEQ-5D, \nSample statistics for \nEQ-5D-VAS; EQ-5D-\nTTO \nOnly mRCC \nExcluded \nCCI\n",
                        "Sub-sections": []
                    }
                ]
            }
        ]
    },
    {
        "Header Number": "9",
        "Title": "List of tables and table shells",
        "Content": "NIS Protocol B1771009                                                        Statistical Analysis Plan \n_____________________________________________________________________ \n \nPFIZER CONFIDENTIAL \nPage 23 of 42 \n \nTable No. \nTitle \nTreatment/\nIndication \nAnalysis set \nDescription \n1.1-6.2 \nNumber of patients by time window \nAll \nSafety, EAS \n.1 Number of patients by visit  \n.2 Number of visits by time window (table may be \nomitted, if only very few documented visits were \ncondensed into one time window) \n1.2 \nDemography \n \n \n \n1.2-1 \nDemographic variables \nAll \nSafety, EAS \nSequence analysis \nage, sex, body height \n1.2-2 \nTime-varying demographic variables \nAll \nSafety, EAS \nSequence analysis \nWeight, BMI by time window \n1.3 \nMedical and oncological history \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n1.3-1.3 \nCurrent manifestations \nMCL \nSAFETY, EAS \nFrequency tables for locations of manifestations \n1.3-1.4 \nTumor anamnesis - other information \nGIST \nSAFETY, EAS \n.1 Frequency table for size of primary tumor, sample \nstatistics for number of mitoses, frequency table for \nprimary mutation analysis performed?, frequency \ntable for type of KIT-mutation \n.2 Frequency table for mutation analysis performed \nin recidive?, frequency table for type of mutation \n \n  \n \n \n \n1.3-3 \nECG \nmRCC, \nGIST \nSAFETY, EAS \nFrequency tables for normal/abnormal ECG by time \nwindow \nCCI\nCCI\nCCI\nCCI\nNIS Protocol B1771009                                                        Statistical Analysis Plan \n_____________________________________________________________________ \n \nPFIZER CONFIDENTIAL \nPage 24 of 42 \n \nTable No. \nTitle \nTreatment/\nIndication \nAnalysis set \nDescription \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \n  \n  \n  \n \n \n \n \n \n \n \n \n \n \n \n \nCCI\nCCI\nNIS Protocol B1771009                                                        Statistical Analysis Plan \n_____________________________________________________________________ \n \nPFIZER CONFIDENTIAL \nPage 25 of 42 \n \nTable No. \nTitle \nTreatment/\nIndication \nAnalysis set \nDescription \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n, number \nof transplantations, R0 resection reached \nCCI\nCCI\nNIS Protocol B1771009                                                        Statistical Analysis Plan \n_____________________________________________________________________ \n \nPFIZER CONFIDENTIAL \nPage 26 of 42 \n \nTable No. \nTitle \nTreatment/\nIndication \nAnalysis set \nDescription \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nCCI\nCCI\nNIS Protocol B1771009                                                        Statistical Analysis Plan \n_____________________________________________________________________ \n \nPFIZER CONFIDENTIAL \nPage 27 of 42 \n \nTable No. \nTitle \nTreatment/\nIndication \nAnalysis set \nDescription \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n2 \nEffectiveness \n \n \n \n2.1 \nResponse to therapy \n \n \n \n2.1-1 \nCourse of response to therapy \nAll \nEAS \nFrequency table by time window \n(in total and by patient risk groups) \nCCI\nCCI\nNIS Protocol B1771009                                                        Statistical Analysis Plan \n_____________________________________________________________________ \n \nPFIZER CONFIDENTIAL \nPage 28 of 42 \n \nTable No. \nTitle \nTreatment/\nIndication \nAnalysis set \nDescription \n2.1-2 \nBest response \nAll \nEAS \nFrequency table for best response in total and \nconfirmed / not-confirmed (the latter not for \nTorisel\u00ae MCL); \nFrequency table for best response excluding patients \n\u201cnot assessable\u201d only for MCL \nListing of reasons for not assessable best response; \nFrequency table for best response by patient risk \ngroups \n2.1-3 \nUsed diagnosis technique \nAll \nEAS \nCT, Thorax X-ray, MRT, Ultrasonic testing, PET, \nBone scan, Clinical (by time window and for best \nresponse) \n2.2 \nOverall survival \n \n \n \n2.2-1 \nKaplan-Meier estimates for Overall survival \nAll \nEAS \nSequence analysis \nTime to 25%, median and 75% survival with \nconfidence intervals \nincl Kaplan-Meier curve on all patients \n2.2-2 \nKaplan-Meier estimates for Overall survival by \npatient risk groups \nmRCC \nEAS \n.1 Physicians prognosis of patients risk \n.2 Risk groups according to Motzer score \n.3 Risk groups according to modified Motzer score \n.4 Risk groups according to Motzer score for \npretreated patients \n.5 by treatment sequence \n.6 by treatment and treatment line. \n.7 1st line patients by risk (poor vs. non-poor) \n.8 by LD\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffdl incl. Log-rank-\ntest and Kaplan-Meier curves \nCCI\nNIS Protocol B1771009                                                        Statistical Analysis Plan \n_____________________________________________________________________ \n \nPFIZER CONFIDENTIAL \nPage 29 of 42 \n \nTable No. \nTitle \nTreatment/\nIndication \nAnalysis set \nDescription \n2.2-2 \nKaplan-Meier estimates for Overall survival by \npatient risk groups \nMCL \nEAS \n.1 Risk groups according to MIPI score at time of \nprimary diagnosis \n.2 Risk groups according to current MIPI score \n.3 2nd and 3rd line \n.4 2nd to 4th line \n.5 4th line and beyond \n.6 5th line and beyond \n.7 Patients with OR (CR+PR) \n.8 Patients with (MR + SD) \n.9 Patients with clinical benefit (CR+PR+MR+SD) \n.10 Patients \ufffd 65 vs. patients > 65 yrs. \nincluding Kaplan-Meier curves \n.1 OS all patients excluding \u201cnot assessable\u201d patients \n.2 OS patients with OR (CR+PR) vs. (MR+SD) vs. \nPD \n.3 OS patients with clinical benefit \n(CR+PR+MR+SD) vs. PD \n.4 OS Temsirolimus 2nd to 4th line (1 \u2013 3 prior \ntherapies) vs. 5th line and beyond (\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ntherapies) \n.5 OS 2nd to 3rd line Temsirolimus (1 \u2013 2 prior \ntherapies) vs. 4th \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ntherapies) \n2.2-2 \nKaplan-Meier estimates for Overall survival by \npatient risk groups \nGIST \nEAS \n.1 Risk groups according to Fletchers risk table \n.2 Risk groups according to physician\u2019s prognosis \n2.2-3 \nFrequency table of patients status by time \nwindow (survival phase) \nAll \nEAS \n \n2.3 \nProgression free survival \n \n \n \n2.3-1 \nKaplan-Meier estimates for Progression free \nsurvival \nAll \nEAS \nSequence analysis \nTime to 25%, median and 75% survival with \nconfidence intervals \nincluding Kaplan-Meier curve on all patients \nCCI\nNIS Protocol B1771009                                                        Statistical Analysis Plan \n_____________________________________________________________________ \n \nPFIZER CONFIDENTIAL \nPage 30 of 42 \n \nTable No. \nTitle \nTreatment/\nIndication \nAnalysis set \nDescription \n2.3-2 \nKaplan-Meier estimates for Progression free \nsurvival by patient risk groups \nmRCC \nEAS \n.1 Physicians prognosis of patients risk \n.2 Risk groups according to Motzer score \n.3 Risk groups according to modified Motzer score \n.4 Risk groups according to Motzer score for \npretreated patients \n5 by treatment sequence \n.6 1st line patients \n.7 1st line patients by risk (poor vs. non-poor) \n.8 2nd line vs. higher lines \n.9 2nd vs. 3rd line vs. higher lines \n\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd \n\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd) vs high (> 300 U/l)  \n.12 by histology (clear cell vs. other) \nKaplan-Meier curves incl Log-Rank-Test \n.1 PFS 1st line vs. 2nd line and higher \n.2 PFS 1st line vs. 2nd line vs. 3rd line and higher \n.\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd \n.4 PFS \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd) vs high (> 300 U/l) \n.5 PFS clear cell histology vs. other histology \nCCI\nNIS Protocol B1771009                                                        Statistical Analysis Plan \n_____________________________________________________________________ \n \nPFIZER CONFIDENTIAL \nPage 31 of 42 \n \nTable No. \nTitle \nTreatment/\nIndication \nAnalysis set \nDescription \n2.3-2 \nKaplan-Meier estimates for Progression free \nsurvival by patient risk groups \nMCL \nEAS \n.1 Risk groups according to MIPI score at time of \nprimary diagnosis \n.2 Risk groups according to current MIPI score \n.3 2nd and 3rd line \n.4 2nd to 4th line \n.5 4th line and beyond \n.6 5th line and beyond \n.7 Patients with OR (CR+PR) \n.8 Patients with MR + SD \n.9 Patients with clinical benefit (CR+PR+MR+SD) \nKaplan-Meier curves incl. Log-Rank-Test \n.1 PFS all patients excluding \u201cnot assessable\u201d \npatients \n.2 PFS patients with OR (CR+PR) vs. (MR+SD) \n.3 PFS patients with clinical benefit \n(CR+PR+MR+SD) \n.4 PFS Temsirolimus 2nd to 4th line (1 \u2013 3 prior \ntherapies) vs. 5th \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ntherapies) \n.5 PFS 2nd to 3rd line Temsirolimus (1 \u2013 2 prior \ntherapies) vs. 4th \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ntherapies) \n2.3-2 \nKaplan-Meier estimates for Progression free \nsurvival by patient risk groups \nGIST \nEAS \n.1 Risk groups according to Fletchers risk table \n.2 Risk groups according to physician\u2019s prognosis \n2.4 \nPhysician\u2019s global assessment \n \n \n \n2.4 \nPhysician\u2019s global assessment of effectiveness \nmRCC \nEAS \nFrequency table by time windows and for the last \ndocumented visit: total and by physician\u2019s prognosis \nof patients risk and by risk groups according to \nMotzer score, modified Motzer score and Motzer \nscore for pretreated patients. \n2.4 \nPhysician\u2019s global assessment of effectiveness \nMCL \nEAS \nFrequency table by time windows and for the last \ndocumented visit: total and by risk groups according \nto MIPI score at time of primary diagnosis and \naccording to current MIPI score. \nCCI\nNIS Protocol B1771009                                                        Statistical Analysis Plan \n_____________________________________________________________________ \n \nPFIZER CONFIDENTIAL \nPage 32 of 42 \n \nTable No. \nTitle \nTreatment/\nIndication \nAnalysis set \nDescription \n2.4 \nPhysician\u2019s global assessment of effectiveness \nGIST \nEAS \nFrequency table by time windows and for the last \ndocumented visit: total and by physician\u2019s prognosis \nof patients risk and by risk groups according to \nFletchers risk table. \n2.5 \nCourse of Karnofsky performance status \nscale \n \n \n \n2.5 \nCourse of Karnofsky performance status scale \nmRCC, \nGIST \nEAS \nSequence analysis for \nmRCC \nSample statistics by time windows and for the last \ndocumented visit, including absolute and relative \ndifferences to baseline \n(in total and by patient risk groups) \n2.5 \nCourse of ECOG performance status and B-\nsymptoms \n \n \n \n2.5-1 \nCourse of ECOG performance status \nMCL \nEAS \nFrequency table by time windows and for the last \ndocumented visit, shift table for differences to \nbaseline \n(in total and by patient risk groups) \n2.5-2 \nCourse of B-symptoms \nMCL \nEAS \nFrequency table by time windows and for the last \ndocumented visit \n2.6 \nFKSI-15: Course \n \n \n \n2.6-1 \nCourse of FKSI-15 score \nmRCC \nEAS \nSequence analysis \nSample statistics by time windows and for the last \ndocumented visit and absolute and relative change to \nbaseline. \n2.6-2 \nCourse of FKSI-DRS score \nmRCC \nEAS \nSequence analysis \nSample statistics by time windows and for the last \ndocumented visit and absolute and relative change to \nbaseline. \n2.6-3 \nCourse of FKSI domains \nmRCC \nEAS \nSequence analysis \nSample statistics by time windows and for the last \ndocumented visit and absolute and relative change to \nbaseline. \n2.7 \nEQ-5D: Course \n \n \n \n2.7-1 \nCourse of EQ-5D: domains \nmRCC \nEAS \nSequence analysis \nFrequency tables by time window and for the last \ndocumented visit and shift tables to baseline \n2.7-2 \nCourse of EQ-5D-VAS \nmRCC \nEAS \nSequence analysis \nSample statistics by time windows and for the last \ndocumented visit and absolute and relative change to \nbaseline. \nCCI\nNIS Protocol B1771009                                                        Statistical Analysis Plan \n_____________________________________________________________________ \n \nPFIZER CONFIDENTIAL \nPage 33 of 42 \n \nTable No. \nTitle \nTreatment/\nIndication \nAnalysis set \nDescription \n2.7-3 \nCourse of EQ-5D: TTO \nmRCC \nEAS \nSequence analysis \nSample statistics by time windows and for the last \ndocumented visit and absolute and relative change to \nbaseline. \n3 \nSafety \n \n \n \n3.1 \nDisplay of adverse events (AE) \n \n \n \n3.1-1.1 \nSummary of adverse events \nAll \nSafety \nNo. / % of patients \n- at risk \n- with AE \n- with drug related AE \n- with AE related to Pfizer treatment \n- with AE related to interim treatment \n\u2013 with SAE \n\u2013 with drug related SAE \n- with SAE related to Pfizer treatment \n- with SAE related to interim treatment \n- with AE leading to permanent discontinuation of \nTorisel\u00ae/ Sutent\u00ae / Inlyta\u00ae \n- with drug related AE leading to permanent \ndiscontinuation of Torisel\u00ae/ Sutent\u00ae / Inlyta \u00ae \n- with SAE leading to permanent discontinuation of \nTorisel\u00ae/ Sutent\u00ae / Inlyta \u00ae \n- with drug related SAE leading to permanent \ndiscontinuation of Torisel\u00ae/ Sutent\u00ae / Inlyta \u00ae \n- Death \n \nNo. / %  of AE \n- all AE \n- drug related \n- related to Pfizer treatment  \n- related to interim treatment  \n \n- SAE  \n- drug related SAE \n- SAE related to Pfizer treatment  \n- SAE related to interim treatment \nCCI\nNIS Protocol B1771009                                                        Statistical Analysis Plan \n_____________________________________________________________________ \n \nPFIZER CONFIDENTIAL \nPage 34 of 42 \n \nTable No. \nTitle \nTreatment/\nIndication \nAnalysis set \nDescription \n \n.1 total \n.2 by treatment sequence \n.3 by line \n3.1-1.2 \nSummary of adverse events by concomitant \nCYP3A4 inducing or inhibiting medications \nTorisel\u00ae \nmRCC / \nMCL \nSafety \nrepeat table 3.1-1.1 by subgroups according to \nCYP3A4 inducing or inhibiting medication (if \nnumber of patients with these medications is \nsufficiently large \n3.1-2 \nAll adverse events (by patients) \nAll \nSafety \nIncidence rates overall and for Primary System \nOrgan Classes (PSOC) and preferred terms of \nMedDRA (non-serious/serious as columns)  \n \n.1 total \n.2 by treatment sequence \n.3 by line \n3.1-3 \nAE by severity (NCI-CTC grade) \nAll \nSafety \nIncidence rates overall and for PSOC and preferred \nterms of MedDRA  \nseverity: max. NCI-CTC grade within patient, \nPSOC, preferred term resp.(non-serious/serious as \ncolumns) \n3.1-4 \nAE with relationship to study drug \nAll \nSafety \nIncidence rates overall and for PSOC and preferred \nterms of MedDRA (non-serious/serious as columns) \n3.1-5 \nAE with action taken \u201cStudy medication \npermanently discontinued\u201d \nAll \nSafety \nIncidence rates overall and for PSOC and preferred \nterms of MedDRA (non-serious/serious as columns) \n3.1-6 \nAE by outcome (event basis) \nAll \nSafety \nNumber of events overall and for PSOC and \npreferred terms of MedDRA \n3.1-7 \nTreatment emergent AE: action taken (event \nbasis) \nAll \nSafety \nNumber of events overall and for PSOC and \npreferred terms of MedDRA \n3.2 \nDeaths, other serious and significant adverse \nevents \n \n \n \n3.2-1.1 \nListing of deaths  \nAll \nSafety \nSorted by patient \n3.2-1.2 \nReason for death \nAll \nSafety \nFrequency table \n3.2-1.3 \nListing of serious adverse events (SAE, except \ndeaths) \nAll \nSafety \nSorted by patient \nCCI\nNIS Protocol B1771009                                                        Statistical Analysis Plan \n_____________________________________________________________________ \n \nPFIZER CONFIDENTIAL \nPage 35 of 42 \n \nTable No. \nTitle \nTreatment/\nIndication \nAnalysis set \nDescription \n3.2-1.4 \nListing of SAE with outcome study treatment \npermanently discontinued \nAll \nSafety \nSorted by patient \n3.3 \nLaboratory values \n \n \n \n3.3-1 \nHematology \n \n \n \n3.3-1 \nLaboratory values: hematology \u2013 study course  \nAll \nSafety \n.x per parameter \nSample statistics by visit, including difference and \nrelative changes to baseline \n3.3-2 \nClinical chemistry \n \n \n \n3.3-2 \nLaboratory values: clinical chemistry- study \ncourse  \nAll \nSafety \n.x per parameter \nSample statistics by visit, including difference and \nrelative changes to baseline \n3.4 \nGlobal tolerability assessment \n \n \n \n3.4 \nPhysician\u2019s global tolerability assessment \nAll \nSafety \nFrequency table by time windows and for the last \ndocumented visit \n3.5 \nVital signs, ECG, echocardiography and pain \n \n \n \n3.5-1 \nCourse of blood pressure \nmRCC \nSafety \nSample statistics by time windows \n3.5-2 \nAssessment of echocardiography \nmRCC \nSafety \nFrequency table by visit \n3.5-3 \nCourse of pain \nmRCC \nSafety \nSample statistics by time windows \nListing \nListing of AE \nAll \nSafety \n \nListing \nData listing for patients included under \nAmendment VI \nmRCC \nAll \ndemographic information, previous local and \nsystemic therapy, duration of therapy (by Pfizer \ntherapy, by non-Pfizer treatment), overall survival, \nprogression free survival, course of Karnofsky \nperformance scale, course of FKSI-15 and EQ-5D \n \n \nCCI\n",
        "Sub-sections": []
    },
    {
        "Header Number": "10",
        "Title": "References",
        "Content": "",
        "Sub-sections": []
    },
    {
        "Header Number": "11",
        "Title": "APPENDICES",
        "Content": "   ",
        "Sub-sections": [
            {
                "Header Number": "11.1",
                "Title": "APPENDIX 1: DATA DERIVATION DETAILS",
                "Content": "  ",
                "Sub-sections": [
                    {
                        "Header Number": "N/A",
                        "Title": "A1.1 Definition and use of visit windows in reporting",
                        "Content": " Time points for follow-up visits are not determined by the study protocol. It is only suggested to perform those every 8 to 12 weeks. In order to be able to perform statistical analyses, documented visits will be transferred into corresponding time windows. The definition of single time windows can be taken from the following table:  Treatment Phase 1 Treatment Phase 2 Treatment Phase 3 Treatment Phase 4 Treatment Phase 5 Treatment Phase 6 Weeks after Baseline 0 to 15 16 to 25 26 to 35 36 to 45 46 to 55 56 to 65  Treatment Phase 7 Treatment Phase 8 Treatment Phase 9 Treatment Phase 10 Treatment Phase 11 and so on... Weeks after Baseline 66 to 75 76 to 85 86 to 95 96 to 105 106 to 115 ...  Survival 1 Survival 2 Survival 3 Survival 4 Survival 5 and so on... Months after discontinuation  0 to 15 16 to 21 22 to 27 28 to 33 34 to 39 ...  CCICCINIS Protocol B1771009                                                        Statistical Analysis Plan _____________________________________________________________________  PFIZER CONFIDENTIAL  Page 37 of 42  In case more than one visit was performed within one time window, than the later one will be used for analyses \u201cby time windows\u201d with the following exceptions: \ufffd Adverse events will be analyzed from all documented visits. \ufffd Duration of PFS will be determined using the first occurrence of a progression of disease. The study phase while patients are treated with Torisel\u00ae/Sutent\u00ae is defined as follow-up phase. The follow-up of subjects after discontinuation of Torisel\u00ae/Sutent\u00ae is defined as survival phase.  ",
                        "Sub-sections": []
                    },
                    {
                        "Header Number": "N/A",
                        "Title": "A1.2 Definition of Analysis Populations/Sets",
                        "Content": "  Not applicable.  ",
                        "Sub-sections": []
                    },
                    {
                        "Header Number": "N/A",
                        "Title": "A1.3 Further Definition of Endpoints",
                        "Content": " ",
                        "Sub-sections": [
                            {
                                "Header Number": "N/A",
                                "Title": "Demography",
                                "Content": " Age (years) = (date of baseline visit \u2013 date of birth + 1)/365.25 BMI = body weight (kg) / body height (m)**2 ",
                                "Sub-sections": []
                            },
                            {
                                "Header Number": "N/A",
                                "Title": "Oncological history",
                                "Content": " For computation of duration of RCC, MCL and GIST and time since first confirmed metastasis (not for MCL) an arbitrary day 1 will be added and thereafter the SAS function for computing with date values will be used. Duration of RCC/MCL/GIST (months) = (1/month/year of start of Torisel\u00ae/Sutent\u00ae/Inlyta\u00ae treatment \u2013 1/month/year of date of histological confirmation of RCC/MCL/GIST)*12/365.25 First metastases (months) = (1/month/year of baseline visit \u2013 1/month/year of date of first confirmation of metastasis)*12/365.25 ",
                                "Sub-sections": []
                            },
                            {
                                "Header Number": "N/A",
                                "Title": "Survival",
                                "Content": " In case an event (either death or progression) was present and date of event was documented, the following definitions was used: CCICCINIS Protocol B1771009                                                        Statistical Analysis Plan \n_____________________________________________________________________ \n \nPFIZER CONFIDENTIAL \n \nPage 38 of 42 \n \nOverall Survival (OS, months) = (date of death \u2013 date of baseline visit +1)/365.25 *12 \nProgression Free Survival (PFS, months) = (minimum of (date of death, date of \nprogression) \u2013 date of baseline visit + 1)/365.25 * 12. \nIn case information on dates were partly or completely missing or contradictory, the \nfollowing was done: \n\ufffd PFS: \no the presence of a progression was confirmed, but no date was documented: \nif date of last intake of study medication was given, this date was used as \ndate of progression, otherwise the date of the last visit with a documented \n\u201cnon-progression (e.g. SD)\u201d was used as date of progression. \no the presence of a progression was confirmed, but dates within a visit and on \nfinal documentation were contradictory, the prior date was used. \no in case a death was documented within a survival follow-up/ within \nsequence 2 for subjects from sequence 1, but no progression was \ndocumented within regular study, the date of last visit + 1 day was used as \ndate of progression. \no in case no progression was documented, subject was censored with the latest \navailable contact date / assessment date within study/within sequence. \no in case these rules led to a missing duration or a negative duration, duration \nwas set to \u201c1 day\u201d. \n\ufffd OS: \no in case a death was documented, but date of death was unknown, the date of \ndeath was substituted with the latest available date for the patient (last \nvisit, last contact date, date of assessment) \no in case no death was documented, subject was censored with the latest \navailable contact date / assessment date within study. \no in case these rules led to a missing duration or a negative duration, duration \nwas set to maximum of (PFS,\u201c1 day\u201d). \nCCI\nCCI\nNIS Protocol B1771009                                                        Statistical Analysis Plan _____________________________________________________________________  PFIZER CONFIDENTIAL  Page 39 of 42  ",
                                "Sub-sections": []
                            },
                            {
                                "Header Number": "N/A",
                                "Title": "Response to therapy (Recist criteria/ Cheson criteria)",
                                "Content": " Response to therapy according to the Recist/ Cheson criteria will be analyzed using the physician\u2019s assessment as documented in the CRF. As neither \u201csize of lesion\u201d, \u201cnew lesions\u201d or \u201cincrease in size\u201d are defined as key fields, contradictory answers will not overvote physicians assessment. \u201eBest response\u201c will be analyzed using the physician\u2019s assessment at final visit. If \u201eBest response\u201c is missing it will be determined from the best response documented during previous follow-up visits.  ",
                                "Sub-sections": []
                            },
                            {
                                "Header Number": "N/A",
                                "Title": "Treatment",
                                "Content": "  duration (weeks) = (date of death or date of drop-out or date of end of treatment with Torisel\u00ae/ Sutent\u00ae - date of first infusion within the registry + 1)/365.25 * 52. ",
                                "Sub-sections": []
                            },
                            {
                                "Header Number": "N/A",
                                "Title": "Therapy line",
                                "Content": " for patients with mRCC: \ufffd Splitted therapy (due to coding) was only counted as one therapy line. \ufffd All medication with an identical start date was counted as one therapy line. \ufffd Interferons, interleukins and immunochemotherapies were summarized as \u201ccytokines\u201d. \ufffd Ongoing treatment with the medication documented was not counted as line. \ufffd Bisphosphonates and other supplementary treatment will not be considered. for patients with MCL: \ufffd Splitted therapy (due to coding) was only counted as one therapy line. \ufffd All medication with an identical start date was counted as one therapy line. \ufffd Rituximab maintenance therapy and stem cell transplantation, both connected with previous immunochemotherapy (ATC L01 Antineoplastic agents and L03 Immunostimulants), were not counted as line. Rituximub were counted as maintenance therapy, if \ufffd physician\u2019s comment contained free text / phrases like \u201cErhaltung\u201d, \u201cErhalt\u201d, \u201cMaintenance\u201d or \ufffd (last therapy prior to Rituximab resulted in remission (CR, PR or MR) and \ufffd Rituximab was started directly after the last therapy (at most one therapy free month was tolerable).)  CCICCINIS Protocol B1771009                                                        Statistical Analysis Plan _____________________________________________________________________  PFIZER CONFIDENTIAL  Page 40 of 42   For calculation of the  score documented values for questions 1-6, 8,9, 11, 12 and 14 will be reversed by subtracting the documented value from 4. All original scores (for questions 7, 10, 13 and 15) and all reversed scores will be summed, multiplied by 15 and devided by the number of answered questions resulting in a score within a range from 0 to 60. The  score cannot be determined if more than 7 questions are not answered. FKSI-DRS score will be calculated like the  score considering only questions 1, 3, 4, 5, 6, 8, 11, 12 and 14 (multiply by 9). FKSI-DRS cannot be determined if more than 4 questions are not answered. The 4 domains of  will be calculated like the ",
                                "Sub-sections": []
                            },
                            {
                                "Header Number": "N/A",
                                "Title": "FKSI-15",
                                "Content": " For calculation of the  score documented values for questions 1-6, 8,9, 11, 12 and 14 will be reversed by subtracting the documented value from 4. All original scores (for questions 7, 10, 13 and 15) and all reversed scores will be summed, multiplied by 15 and devided by the number of answered questions resulting in a score within a range from 0 to 60. The  score cannot be determined if more than 7 questions are not answered. FKSI-DRS score will be calculated like the  score considering only questions 1, 3, 4, 5, 6, 8, 11, 12 and 14 (multiply by 9). FKSI-DRS cannot be determined if more than 4 questions are not answered. The 4 domains of  will be calculated like the  score. The following tables shows domains and related questions, multiplyer and maximal number of unanswered questions in order to give a valid score.  Domain Questions Multiplyer Maximal number of unanswered questions Signs and symptoms 1, 2, 3, 4, 5, 6, 12, 13 8 4 Respiratory symptoms 8, 11 2 1 Quality of life 7, 10, 13, 15 4 2 Emotional symptom 9 1 0  ",
                                "Sub-sections": []
                            },
                            {
                                "Header Number": "N/A",
                                "Title": "EQ-5D (TTO)",
                                "Content": " EQ-5D-TTO will be calculated from EQ-5D raw values according to the following formula (Greiner, W. et al. 2005): EQ-5D-TTO = 0.999 - 0.099 * (1*Subject has some problems with walking around    + 2 * Subject cannot walk around)  - 0.087 * (1*Subject has some problems with self-care   + 2 * Subject has extreme problems with self-care) \u2013 0.112 * (1*Subject states moderate pain or discomfort   + 2 * Subject has extreme pain or discomfort) \u2013 0.129 * (Subject cannot walk around) \u2013 0.091 * (Subject has extreme pain or discomfort) \u2013 0.065 * (Subject is extremely anxious or depressive) \u2013 0.323 * (Subject states major problems in at least one    dimension). CCICCINIS Protocol B1771009                                                        Statistical Analysis Plan _____________________________________________________________________  PFIZER CONFIDENTIAL  Page 41 of 42  EQ-5D-TTO-values range from \u20130.205 to 0.999.  Additional queries were written in the following cases: \ufffd calcium > 10 mmol/L \ufffd albumin > 100 g/L \ufffd hemoglobin > 20 g/dL \ufffd LDH < 80 U/L or > 1000 U/L \ufffd albumin in % of total protein. ",
                                "Sub-sections": []
                            },
                            {
                                "Header Number": "N/A",
                                "Title": "Laboratory values",
                                "Content": " Additional queries were written in the following cases: \ufffd calcium > 10 mmol/L \ufffd albumin > 100 g/L \ufffd hemoglobin > 20 g/dL \ufffd LDH < 80 U/L or > 1000 U/L \ufffd albumin in % of total protein.  were set to \u201cmissing\u201d if the documented values were outside the ranges given in the following table: Laboratory parameter Lower plausibility range Upper plausibility range Neutrophils 6% 100% Lymphocytes 2.5% 85% Monocytes - 26% Eosinophils - 16% Basophils - 5% Leukocytes - 28 G/L Platelets - 1000 G/L Hemoglobin* - 20 g/dL Creatinine - 12 mg/dL Calcium* - 10 mmol/L Sodium - 320 mmol/L Potassium - 15 mmol/L Phosphate - 4 mmol/L Magnesium - 7 mmol/L ALT (GPT) 1 U/L 1400 U/L CCICCINIS Protocol B1771009                                                        Statistical Analysis Plan _____________________________________________________________________  PFIZER CONFIDENTIAL  Page 42 of 42  Laboratory parameter Lower plausibility range Upper plausibility range AST (GOT) 1 U/L 1400 U/L Gamma-GT 1 U/L 1400 U/L Alkaline Phosphatase 1 U/L 5100 U/L Total bilirubin - 25 mg/dL Albumin - 100 g/L LDH* 80 U/L 1000 U/L Cholesterol - 26 mmol/L Triglycerides - 35 mmol/L HbA1c 1% 10% Glucose - -** TSH - 21 mU/L beta-2 Microglobulin - - *: Risk factors according to Motzer score will be set prior to check on plausibility. **: No plausibility range defined as values do not need to be fasting glucose values. ",
                                "Sub-sections": []
                            },
                            {
                                "Header Number": "N/A",
                                "Title": "CYP3A4-inducing and inhibiting substances",
                                "Content": " A combination of Torisel\u00ae and CYP3A4 influencing substances should be handled carefully. Thus documented concomitant medication will be checked manually for CYP3A4 inducing and inhibiting substances by the medical expert.  If the number of patients who received either CYP3A4 inducing or inhibiting substances is sufficiently large, parts of the safety analysis will be repeated for those subgroups. ",
                                "Sub-sections": []
                            },
                            {
                                "Header Number": "N/A",
                                "Title": "Comorbidities",
                                "Content": "",
                                "Sub-sections": []
                            }
                        ]
                    }
                ]
            }
        ]
    }
]